Show simple item record

dc.contributor.authorBeauchamp, LC
dc.contributor.authorVillemagne, VL
dc.contributor.authorFinkelstein, D
dc.contributor.authorDore, V
dc.contributor.authorBush, A
dc.contributor.authorBarnham, KJ
dc.contributor.authorRowe, CC
dc.date.accessioned2020-11-17T04:14:49Z
dc.date.available2020-11-17T04:14:49Z
dc.date.issued2020-10-23
dc.identifierpii: 10.1038/s41598-020-74495-x
dc.identifier.citationBeauchamp, L. C., Villemagne, V. L., Finkelstein, D., Dore, V., Bush, A., Barnham, K. J. & Rowe, C. C. (2020). Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism. SCIENTIFIC REPORTS, 10 (1), https://doi.org/10.1038/s41598-020-74495-x.
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/11343/251747
dc.description.abstractMotor deficits in parkinsonism are caused by degeneration of dopaminergic nigral neurons. The success of disease-modifying therapies relies on early detection of the underlying pathological process, leading to early interventions in the disease phenotype. Healthy (n = 16), REM sleep behavior disorder (RBD) (n = 14), dementia with Lewy bodies (n = 10), and Parkinson's disease (PD) (n = 20) participants underwent 18F-AV133 vesicular monoamine transporter type-2 (VMAT2) PET to determine the integrity of the nigrostriatal pathway. Clinical, neurophysiological and neuropsychological testing was conducted to assess parkinsonian symptoms. There was reduced VMAT2 levels in RBD participants in the caudate and putamen, indicating nigrostriatal degeneration. RBD patients also presented with hyposmia and anxiety, non-motor symptoms associated with parkinsonism. 18F-AV133 VMAT2 PET allows identification of underlying nigrostriatal degeneration in RBD patients. These findings align with observations of concurrent non-motor symptoms in PD and RBD participants of the Parkinson's Progression Markers Initiative. Together, these findings suggest that RBD subjects have prodromal parkinsonism supporting the concept of conducting neuroprotective therapeutic trials in RBD-enriched cohorts. Ongoing longitudinal follow-up of these subjects will allow us to determine the time-window of clinical progression.
dc.languageEnglish
dc.publisherNATURE RESEARCH
dc.titleReduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism
dc.typeJournal Article
dc.identifier.doi10.1038/s41598-020-74495-x
melbourne.affiliation.departmentFlorey Department of Neuroscience and Mental Health
melbourne.source.titleScientific Reports
melbourne.source.volume10
melbourne.source.issue1
melbourne.source.pages17631-
dc.rights.licenseCC BY
melbourne.elementsid1470699
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584593
melbourne.contributor.authorBush, Ashley
melbourne.contributor.authorFinkelstein, David
melbourne.contributor.authorBarnham, Kevin
melbourne.contributor.authorRowe, Christopher
melbourne.contributor.authorBeauchamp, Leah
dc.identifier.eissn2045-2322
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record